Theralase Technologies Inc. TLTFF

J and J Tar 200 claiming a high CR % for NMIBC

[Infinity]

I would like some comments from anyone who is knowledgable of familiar with this development.  This could potentially affect TLT


https://www.prnewswire.com/news-releases/new-data-from-tar-200-phase-2b-sunrise-1-study-show-84-percent-complete-response-rate-in-patients-with-high-risk-non-muscle-invasive-bladder-cancer-302248316.html#:~:text=About%20TAR%2D200&text=In%20December%202023%2C%20the%20FDA,surgical%20removal%20of%20the%20bladder).

[PrettyPennies]

.....The sun has set on Johnson & Johnson’s SunRISe-2 study. J&J called a halt to the phase 3 bladder cancer trial after an interim look at the data showed the TAR-200 candidate was no better than chemoradiation. https://www.fiercebiotech.com/biotech/jj-stops-phase-3-trial-5b-bladder-cancer-prospect-after-interim-review-flop

[Dumbeldorfwhite]

That's for a completely different indication did you even read the article?

[DJDawg]

Here is a copy paste of my old post on this drug ------ The TAR-200 monotherapy works as you would expect. The protocol is to insert the device into the bladder every 3 weeks for 24 weeks then every 3 months after that. The device contains various drugs that are known to be effective against bladder cancer. The device then releases the drug slowly into the bladder and stay there until swapped

[DJDawg]

Compared to the original post above, there is more recent data TAR-200 monotherapy provides complete response rate of 84% in patients with BCG-unresponsive high-risk NMIBC, based on published data, without the need for re-induction By 12 months the estimated CR is down to 57.4% which is still good but keep in mind that this after a first year in which they are being treated every 3 weeks until 8

[Dumbeldorfwhite]

Probably not going to see a huge drop since the treatment continues for 96 weeks

[Eoganacht]

There is also the safety issue to consider. They reported that 9.4% of the 85 patients (8 patients} experienced a treatment related adverse event greater than grade 3, and 5 of these patients (6%) were removed from the trial as a direct result of the severity of their adverse reaction to the treatment. As a comparison, there is a 0% incidence of serious

[Dumbeldorfwhite]

Pretty simple their results are superior to ours. TLT has blundered their way through this which has allowed everyone to catch up and surpass them. Beyond the obvious such as insanely low enrollment rates and dosing the drug incorrectly, they also either have been unable or unwilling to partner with anyone else which is mind blowing since their patent runs out in the not so distant future so at